Higher Interlukin-6 (IL-6) in Blood Can Predict Cancer Risk in People With Type 2 Diabetes

A simple blood test could help identify individuals with type 2 diabetes who are at a higher risk of developing certain types of cancers, revealed a groundbreaking study presented at the European Association for the Study of Diabetes (EASD) Annual Meeting in Madrid (1^✔ ✔Trusted Source
Individuals with type 2 diabetes who are at higher risk of certain cancers could be identified by a simple blood test, Danish study suggests

Go to source). These cancers, often referred to as obesity-related malignancies (OR cancers), include breast, kidney, womb, thyroid, ovarian, colorectal, pancreatic cancers, and multiple myeloma. The study, led by Mathilde Dahlin Bennetsen from the Steno Diabetes Center Odense, Denmark, offers new insights into how inflammation plays a key role in cancer risk among people with diabetes.

Advertisement

Link Between Type 2 Diabetes and Cancer Risk

People with type 2 diabetes are more susceptible to various health complications, including an increased risk of cancer. One reason for this heightened risk is chronic low-grade inflammation, a condition that commonly affects individuals with both type 2 diabetes and obesity. This inflammation, caused by an overactive immune response, can create an environment in the body that promotes the growth of cancer cells.

According to the study, this persistent inflammation is largely driven by proinflammatory cytokines- proteins produced by the immune system that trigger and sustain inflammation. The research primarily focused on three such cytokines: interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and high sensitivity C-reactive protein (hsCRP). The findings reveal that higher levels of IL-6, in particular, were linked to an increased likelihood of developing obesity-related cancers.

Advertisement

Cytokine Interleukin-6 Linked to Increased Cancer Risk in Individuals with Type 2 Diabetes

The study conducted by Bennetsen and her colleagues examined data from 6,466 participants in the Danish Centre for Strategic Research in Diabetes (DD2) cohort. All participants were newly diagnosed with type 2 diabetes at the time of the study. The median age of the participants was 60.9 years, and about 40.5% of them were women. The researchers analyzed blood samples from the participants to measure levels of IL-6, TNF-alpha, and hsCRP, in an effort to understand their relationship with the development of OR cancers.

Participants were then followed for an average of 8.8 years, during which time 327 individuals developed obesity-related cancers. The researchers found that participants with higher baseline levels of IL-6 had a 51% increased risk of developing these cancers compared to those with the lowest levels of IL-6. Interestingly, TNF-alpha and hsCRP, while associated with inflammation, did not have as strong of a connection to cancer risk as IL-6.

Advertisement

Importance of Interlukin-6 (IL-6) in Predicting Cancer Risk

One of the most significant takeaways from the study is the potential predictive power of IL-6 levels when it comes to cancer risk in people with type 2 diabetes. When the researchers adjusted for various factors such as age, gender, duration of diabetes, alcohol consumption, waist circumference, physical activity, blood sugar control (measured by HbA1c levels), triglyceride levels, and medication use, IL-6 still stood out as a strong indicator of future cancer risk.

In contrast, adding TNF-alpha or hsCRP levels to the predictive model did not improve the ability to identify individuals at risk for obesity-related cancers. This highlights IL-6 as a key biomarker that could one day be used in a simple blood test to determine whether a person with type 2 diabetes is more likely to develop certain cancers.

What Does This Mean for Individuals with Type 2 Diabetes?

Understanding who is at higher risk for cancer could have profound implications for how doctors monitor and treat people with type 2 diabetes. Early detection and personalized treatment plans could make a significant difference in cancer outcomes, leading to better survival rates and improved quality of life. If healthcare providers can identify those at greater risk for cancer, they can offer more targeted screenings and potentially catch cancer at an earlier, more treatable stage.

According to Bennetsen, the lead researcher, more research is needed before a blood test measuring IL-6 can be widely used as a screening tool. However, the findings offer promising evidence that such a test could one day be part of routine diabetes care.

Role of Inflammation in Cancer and Diabetes

Chronic low-grade inflammation is a hallmark of both obesity and type 2 diabetes, and it’s becoming increasingly clear that inflammation also plays a crucial role in cancer development. When fat cells in the body produce inflammatory cytokines like IL-6 and TNF-alpha, it leads to a persistent state of inflammation. Over time, this inflammation damages cells, potentially causing them to mutate and become cancerous.

By identifying those with higher levels of inflammatory markers, such as IL-6, healthcare providers could not only monitor for cancer but also take steps to reduce inflammation through lifestyle changes, medications, or other interventions.

Managing Inflammation and Reducing Cancer Risk in Diabetic Patients

For people with type 2 diabetes, managing inflammation could be a key strategy in lowering their risk of developing certain cancers. Lifestyle factors like maintaining a healthy diet, exercising regularly, and adhering to prescribed treatment plans can help reduce inflammation and improve overall health. Regular check-ups with healthcare providers, including screenings for cancer, are also important in catching any potential issues early.

The findings from Bennetsen’s study reinforce the importance of good diabetes management in not only controlling blood sugar levels but also potentially reducing the risk of serious complications like cancer.

Promising Future for Early Detection of Cancer in Diabetic Patients

The study conducted by Mathilde Dahlin Bennetsen and her team opens up new possibilities for identifying cancer risk in individuals with type 2 diabetes. By focusing on the relationship between inflammation and cancer, the research provides a better understanding of why people with type 2 diabetes are more prone to developing certain cancers.

A simple blood test that measures levels of IL-6 could one day become a valuable tool in identifying high-risk individuals, allowing for more targeted and personalized care. While further research is needed, these findings offer hope for improved cancer outcomes through earlier detection and intervention.

In the meantime, people with type 2 diabetes should continue to prioritize their health by following medical advice, managing their blood sugar levels, and maintaining a healthy lifestyle to help reduce inflammation and lower their risk of developing cancer.

Reference:

1. Individuals with type 2 diabetes who are at higher risk of certain cancers could be identified by a simple blood test, Danish study suggests (https://www.eurekalert.org/news-releases/1055699)

Source-Medindia